References
- Schlesinger N. Anti-interleukin-1 therapy in the management of gout. Curr Rheumatol Rep. 2014;16(2):398-z. Available from: https://www.ncbi.nlm.nih.gov/pubmed/?term=Schlesinger+N.+Anti-interleukin-1+therapy+in+the+management+of+gout10.1007/s11926-013-0398-z
- Cavagna L, Taylor WJ. The Emerging Role of Biotechnological Drugs in the Treatment of Gout. Biomed Res Int [Internet]. 2014;2014( Article ID 264859):1–9. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4009249&tool=pmcentrez&rendertype=abstract
- Rider TG, Jordan KM. The modern management of gout. Rheumatology. 2010;49(1):5–14.10.1093/rheumatology/kep306
- European Medicines Agency [web page]. 1995–2015. [cited 2015 Jan 27]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001109/WC500140963.pdf
- Zhang W, Doherty M, Bardin T. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312–24.10.1136/ard.2006.055269
- Khanna D, Khanna PP, Fitzgerald JD. 2012 American college of rheumatology guidelines for management of gout. Part 2: Therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447–61.10.1002/acr.21773
- Richette P, Doherty M, Pascual E. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016. doi:10.1136/annrheumdis-2016-209707.